Compass Therapeutics Stock Analysis
| CMPX Stock | USD 3.00 0.15 4.76% |
Compass Therapeutics is undervalued with Real Value of 5.52 and Target Price of 13.22. The main objective of Compass Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Compass Therapeutics is worth, separate from its market price. There are two main types of Compass Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Compass Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Compass Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Compass Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. Compass Stock Analysis Notes
About 14.0% of the company shares are held by company insiders. The book value of Compass Therapeutics was currently reported as 0.8. The company recorded a loss per share of 0.4. Compass Therapeutics had not issued any dividends in recent years. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. For more info on Compass Therapeutics please contact the company at 617 500 8099 or go to https://www.compasstherapeutics.com.Compass Therapeutics Investment Alerts
| Compass Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 850 K. Net Loss for the year was (49.38 M) with profit before overhead, payroll, taxes, and interest of 850 K. | |
| Compass Therapeutics currently holds about 132.02 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Compass Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance |
Compass Therapeutics Upcoming and Recent Events
Earnings reports are used by Compass Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Compass Largest EPS Surprises
Earnings surprises can significantly impact Compass Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-28 | 2024-12-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2023-08-03 | 2023-06-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2024-03-21 | 2023-12-31 | -0.09 | -0.11 | -0.02 | 22 |
Compass Therapeutics Environmental, Social, and Governance (ESG) Scores
Compass Therapeutics' ESG score is a quantitative measure that evaluates Compass Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Compass Therapeutics' operations that may have significant financial implications and affect Compass Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Compass Stock Institutional Investors
| Shares | Blue Owl Capital Holdings Lp | 2025-03-31 | 3 M | Geode Capital Management, Llc | 2025-03-31 | 2.4 M | Jpmorgan Chase & Co | 2025-03-31 | 2.2 M | State Street Corp | 2025-03-31 | 1.9 M | Sg Americas Securities, Llc | 2025-03-31 | 940.8 K | Silverarc Capital Management, Llc | 2025-03-31 | 874.9 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 839.2 K | Northern Trust Corp | 2025-03-31 | 803.1 K | Macquarie Group Ltd | 2025-03-31 | 681.5 K | Orbimed Advisors, Llc | 2025-03-31 | 22.4 M | Tang Capital Management Llc | 2025-03-31 | 11.1 M |
Compass Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 414.85 M.Compass Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.39) | (0.41) |
Management Efficiency
Compass Therapeutics has return on total asset (ROA) of (0.2641) % which means that it has lost $0.2641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4131) %, meaning that it created substantial loss on money invested by shareholders. Compass Therapeutics' management efficiency ratios could be used to measure how well Compass Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.37 in 2025. Return On Capital Employed is likely to drop to -0.45 in 2025. Net Tangible Assets is likely to rise to about 219.3 M in 2025, whereas Total Assets are likely to drop slightly above 125.3 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.91 | 0.96 | |
| Tangible Book Value Per Share | 0.91 | 0.96 | |
| Enterprise Value Over EBITDA | (2.95) | (3.10) | |
| Price Book Value Ratio | 1.59 | 1.18 | |
| Enterprise Value Multiple | (2.95) | (3.10) | |
| Price Fair Value | 1.59 | 1.18 | |
| Enterprise Value | 186.3 M | 176.9 M |
Effective leadership at Compass Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Technical Drivers
As of the 19th of July, Compass Therapeutics shows the Mean Deviation of 2.95, downside deviation of 3.82, and Risk Adjusted Performance of 0.2227. Compass Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Compass Therapeutics Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Compass Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Compass Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
Compass Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Compass Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Compass Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Compass Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Compass Therapeutics Outstanding Bonds
Compass Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Compass Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Compass bonds can be classified according to their maturity, which is the date when Compass Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| US20451RAC60 Corp BondUS20451RAC60 | View | |
| US20451RAB87 Corp BondUS20451RAB87 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Compass Minerals International Corp BondUS20451NAG60 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Compass Therapeutics Predictive Daily Indicators
Compass Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Compass Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Compass Therapeutics Forecast Models
Compass Therapeutics' time-series forecasting models are one of many Compass Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Compass Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Compass Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Compass Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Compass shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Compass Therapeutics. By using and applying Compass Stock analysis, traders can create a robust methodology for identifying Compass entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (52.28) | (54.89) | |
| Operating Profit Margin | (59.96) | (62.95) | |
| Net Loss | (52.28) | (54.89) |
Current Compass Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Compass analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Compass analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 13.22 | Strong Buy | 9 | Odds |
Most Compass analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Compass stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Compass Therapeutics, talking to its executives and customers, or listening to Compass conference calls.
Compass Stock Analysis Indicators
Compass Therapeutics stock analysis indicators help investors evaluate how Compass Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Compass Therapeutics shares will generate the highest return on investment. By understating and applying Compass Therapeutics stock analysis, traders can identify Compass Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 24.2 M | |
| Common Stock Shares Outstanding | 137.1 M | |
| Total Stockholder Equity | 125.2 M | |
| Total Cashflows From Investing Activities | 46.8 M | |
| Property Plant And Equipment Net | 7.1 M | |
| Cash And Short Term Investments | 126.7 M | |
| Cash | 43.5 M | |
| Accounts Payable | 2.2 M | |
| Net Debt | -36.8 M | |
| 50 Day M A | 2.3176 | |
| Total Current Liabilities | 8.9 M | |
| Other Operating Expenses | 57.5 M | |
| Non Current Assets Total | 7.7 M | |
| Non Currrent Assets Other | 568 K | |
| Stock Based Compensation | 8.6 M |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.